Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer

Summary

Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty in implementing and continuing standard treatment. The safety, pharmacokinetics, absorbed dose, and efficacy will be evaluated to determine the recommended dose for Phase II clinical trial.

Timeline

Start

2021-11-20

Primary completion

2024-12-31

Completion

2025-03-31

Drugs

Indications